Information Kit

News Articles

 

Publications

 

Videos and other media

 

Awards

 

Scientific Literature

Cancer Research
  • Hao, N.-B. et al. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 948098 (2012).
  • Quatromoni, J. G. & Eruslanov, E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am. J. Transl. Res. 4, 376–89 (2012).
  • Ma, J. et al. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10, 112 (2010).
  • Jensen, T. O. et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J. Clin. Oncol. 27, 3330–7 (2009).
  • He, Y. et al. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One 8, e79769 (2013).
  • Zhang, M. et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J. Ovarian Res. 7, 19 (2014).
  • Kamper, P. et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica 96, 269–76 (2011).
  • Pantano, F. et al. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. J. Cell. Mol. Med. 17, 1415–21 (2013).
  • Edin, S. et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7, e47045 (2012).
  • Lanciotti, M. et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res. Int. 2014, 486798 (2014).
  • Kurahara, H. et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167, e211–9 (2011).
  • Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumour stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011 (New York, NY;331(6024):1612-6.
  • Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature immunology 2010;11(10):889-96.
  • Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 2010;132(2):226-39.
  • Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumour cell growth and suppresses nitric oxide-mediated tumour cytotoxicity. Cancer research 2001;61(3):1100-6.
  • Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumour have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol  2009;27(20):3330-7.
  • Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumour-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC cancer 2010;10:112.
  • Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current opinion in immunology 2010;22(2):231-7.
  • Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumour-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert review of molecular diagnostics 2011;11(1):91-100.
  • Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumour growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer cell 2011;19(1):31-44.
  • Schmid MC, Varner JA. Myeloid cells in the tumour microenvironment: modulation of tumour angiogenesis and tumour inflammation. Journal of oncology;2010:201026.
  • Solinas G, Germano G, Mantovani A, Allavena P. Tumour-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of leukocyte biology 2009;86(5):1065-73.
  • Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-beta-induced IRAK-M expression in tumour-associated macrophages regulates lung tumour growth. Oncogene 2011;30(21):2475-84.
Immune-related disease (Crohn’s disease, ulcerative colitis)
  • Mokry, M. et al. Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology 146, 1040–7 (2014).
  • Hayee, B., Rahman, F. Z., Sewell, G., Smith, A. M. & Segal, A. W. Crohn’s disease as an immunodeficiency. Expert Rev. Clin. Immunol. 6, 585–96 (2010).
  • Vavricka, S. R. & Rogler, G. New insights into the pathogenesis of Crohn’s disease: are they relevant for therapeutic options? Swiss Med. Wkly. 139, 527–34 (2009).
  • Marks, D. J. B. et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet 367, 668–78 (2006).
  • Marks, D. J. B., Rahman, F. Z., Sewell, G. W. & Segal, A. W. Crohn’s disease: an immune deficiency state. Clin. Rev. Allergy Immunol. 38, 20–31 (2010).
  • Kim, R., Emi, M. & Tanabe, K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119, 254–64 (2006).
  • Szondy, Z., Garabuczi, E., Joós, G., Tsay, G. J. & Sarang, Z. Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications. Front. Immunol. 5, 354 (2014).
  • Nagata, S. Apoptosis and autoimmune diseases. Ann. N. Y. Acad. Sci. 1209, 10–6 (2010).
  • Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications in health and disease. The Journal of cell biology 2010;189(7):1059-70.
  •  Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. Journal of internal medicine 2012;271(5):421-8.
  • Korzenik JR. Is Crohn’s disease due to defective immunity? Gut 2007;56(1):2-5.
  • Marks DJ. Defective innate immunity in inflammatory bowel disease: a Crohn’s disease exclusivity? Current opinion in gastroenterology 2011;27(4):328-34.
  • Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet 2006;367(9511):668-78.
  • Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn’s disease: an immune deficiency state. Clinical reviews in allergy & immunology 2010;38(1):20-31.
Autoimmune disease (rheumatoid arthritis)
  • Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nature reviews 2010;6(5):280-9.
  • Khan M, Pelengaris S, Cooper M, Smith C, Evan G, Betteridge J. Oxidised lipoproteins may promote inflammation through the selective delay of engulfment but not binding of apoptotic cells by macrophages. Atherosclerosis 2003;171(1):21-9.
  • Nagata S. Rheumatoid polyarthritis caused by a defect in DNA degradation. Cytokine & growth factor reviews 2008;19(3-4):295-302.
  • Sumida T, Hasunuma T, Asahara H, Maeda T, Nishioka K. Rheumatoid arthritis and apoptosis. Internal medicine (Tokyo, Japan) 1998;37(2):184-8.

Past events:


Past events: